UKHSA Recommends 4CMenB Vaccine for Men Who Have Sex With Men to Prevent Meningococcal Disease
The UK Health Security Agency (UKHSA) continues to recommend the 4CMenB vaccine for men who have sex with men (MSM) to prevent meningococcal disease, according to official guidelines. This recommendation, first introduced in 2014, targets a population at higher risk for meningococcal infections due to social and behavioral factors, though the vaccine is not specifically approved for gonorrhoea prevention, as some reports have suggested.
What is the 4CMenB Vaccine?
The 4CMenB vaccine, also known as Bexsero, is designed to protect against meningococcal group B bacteria, which can cause severe infections such as meningitis and sepsis. The UKHSA emphasizes that the vaccine is not a treatment for gonorrhoea, a bacterial sexually transmitted infection (STI) caused by *Neisseria gonorrhoeae*. However, some studies have explored its potential off-label use in reducing gonorrhoea transmission, though these findings remain controversial and unapproved by regulatory agencies.
Why Is the UKHSA Recommending It?
The UKHSA highlights that MSM are disproportionately affected by meningococcal disease compared to the general population. A 2021 study published in *The Lancet Infectious Diseases* found that this group faces a 10-fold higher risk of invasive meningococcal disease, prompting targeted vaccination efforts. While the vaccine does not directly address gonorrhoea, public health officials note that co-infections and overlapping risk factors between STIs and meningococcal disease justify the recommendation.
Effectiveness and Safety
Clinical trials and real-world data indicate the 4CMenB vaccine is effective in reducing meningococcal group B infections. A 2020 review in *Vaccine* reported a 70–80% reduction in cases among vaccinated MSM. The vaccine is generally well-tolerated, with common side effects including soreness at the injection site and mild fever. The UKHSA advises that individuals should consult their healthcare provider to assess personal risk factors.
What About Gonorrhoea?
Despite some media reports linking the 4CMenB vaccine to gonorrhoea prevention, official guidance from the UKHSA and the World Health Organization (WHO) clarifies that no vaccine is currently approved for this purpose. The WHO recommends regular STI screening, antimicrobial therapy, and behavioral interventions to reduce gonorrhoea transmission. Researchers are investigating new approaches, including combination vaccines, but none are available yet.
How Does This Impact Public Health?
The UKHSA’s continued focus on meningococcal vaccination for MSM reflects broader efforts to address health disparities in marginalized communities. Public health experts stress the importance of clear communication to avoid confusion between vaccines targeting different pathogens. As antibiotic resistance in *N. gonorrhoeae* rises, alternative strategies—such as improving access to testing and treatment—remain critical.
What’s Next for Vaccine Development?
While the 4CMenB vaccine remains a cornerstone of meningococcal prevention, ongoing research aims to develop broader protections against STIs. A 2023 study in *Nature Medicine* explored a dual vaccine targeting both *N. gonorrhoeae* and *Chlamydia trachomatis*, but large-scale trials are still in early stages. Until then, health officials urge adherence to existing prevention measures.
For more information, visit the UKHSA’s 4CMenB vaccine page or consult a healthcare provider.